HY-P9950-1mg
|
MedChemexpress LLC
|
Omalizumab [CAS 242138-07-4]
|
|
COVID-19-immunoregulation
|
|
HY-P9950-5mg
|
MedChemexpress LLC
|
Omalizumab [CAS 242138-07-4]
|
|
COVID-19-immunoregulation
|
|
HY-P99573-1mg
|
MedChemexpress LLC
|
Tebotelimab [CAS 2245725-04-4]
|
|
COVID-19-immunoregulation
|
|
HY-P99573-10mg
|
MedChemexpress LLC
|
Tebotelimab [CAS 2245725-04-4]
|
|
COVID-19-immunoregulation
|
|
HY-P99573-5mg
|
MedChemexpress LLC
|
Tebotelimab [CAS 2245725-04-4]
|
|
COVID-19-immunoregulation
|
|
HY-P99382-1mg
|
MedChemexpress LLC
|
Vopratelimab [CAS 2039148-04-2]
|
|
COVID-19-immunoregulation
|
|
HY-P99382-10mg
|
MedChemexpress LLC
|
Vopratelimab [CAS 2039148-04-2]
|
|
COVID-19-immunoregulation
|
|
HY-P99382-5mg
|
MedChemexpress LLC
|
Vopratelimab [CAS 2039148-04-2]
|
|
COVID-19-immunoregulation
|
|
HY-P99236-1mg
|
MedChemexpress LLC
|
Bexmarilimab [CAS 2259301-27-2]
|
|
COVID-19-immunoregulation
|
|
HY-P99236-10mg
|
MedChemexpress LLC
|
Bexmarilimab [CAS 2259301-27-2]
|
|
COVID-19-immunoregulation
|
|
HY-P99236-5mg
|
MedChemexpress LLC
|
Bexmarilimab [CAS 2259301-27-2]
|
|
COVID-19-immunoregulation
|
|
HY-P99287-1mg
|
MedChemexpress LLC
|
Elsilimomab [CAS 468715-71-1]
|
|
COVID-19-immunoregulation
|
|
HY-P99287-10mg
|
MedChemexpress LLC
|
Elsilimomab [CAS 468715-71-1]
|
|
COVID-19-immunoregulation
|
|
HY-P99287-5mg
|
MedChemexpress LLC
|
Elsilimomab [CAS 468715-71-1]
|
|
COVID-19-immunoregulation
|
|
HY-P99110-1mg
|
MedChemexpress LLC
|
Lanadelumab [CAS 1426055-14-2]
|
|
COVID-19-immunoregulation
|
|
HY-P99110-10mg
|
MedChemexpress LLC
|
Lanadelumab [CAS 1426055-14-2]
|
|
COVID-19-immunoregulation
|
|
HY-P99110-5mg
|
MedChemexpress LLC
|
Lanadelumab [CAS 1426055-14-2]
|
|
COVID-19-immunoregulation
|
|